Annals of hepatology最新文献

{"title":"Reassessing the protective role of nonselective β-blockers against hepatocellular carcinoma development in patients with liver cirrhosis.","authors":"Enmin Gong, Yuxian You, Fengsong Chen","doi":"10.1016/j.aohep.2026.102446","DOIUrl":"10.1016/j.aohep.2026.102446","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102446"},"PeriodicalIF":6.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149056913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Periodontal health in MASLD: A missing component of multidisciplinary care.","authors":"Yang Hu, Jinlan Meng","doi":"10.1016/j.aohep.2026.102445","DOIUrl":"10.1016/j.aohep.2026.102445","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102445"},"PeriodicalIF":6.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149056908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond gut-directed therapy: A neuro-purification escalation pathway for severe hepatic encephalopathy.","authors":"Jiajia Gong, Yan Chu","doi":"10.1016/j.aohep.2026.102444","DOIUrl":"10.1016/j.aohep.2026.102444","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102444"},"PeriodicalIF":6.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149056914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"drug-induced liver injury: A real-world pharmacovigilance study using the FDA adverse event reporting system database (2004-2024)\".","authors":"Prateek Pandey, Amit Kumar Mishra, Shubham Singh","doi":"10.1016/j.aohep.2026.102447","DOIUrl":"10.1016/j.aohep.2026.102447","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102447"},"PeriodicalIF":6.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149056895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the impact factor: What readers and authors value in scientific journals.","authors":"Shigeki Matsubara","doi":"10.1016/j.aohep.2026.102450","DOIUrl":"10.1016/j.aohep.2026.102450","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102450"},"PeriodicalIF":6.2,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149056961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cohort study of physical activity, gut microbiota, serum metabolites, and the risk of steatotic liver disease.","authors":"Shaoxian Liang, Yaling Shao, Hairui Qin, Meiling Li, Hong Xu, Junyi Zhang, Zisuo Sun, Hongjuan Cao, Xinsheng Qin, Zhuang Zhang, Wanshui Yang","doi":"10.1016/j.aohep.2026.102443","DOIUrl":"10.1016/j.aohep.2026.102443","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Prospective evidence on the association between physical activity (PA) and steatotic liver disease (SLD) risk is limited. Gut microbiota profiles and metabolites associated with PA remain unclear.</p><p><strong>Patients and methods: </strong>We investigated the association between PA and SLD risk in a cohort of 2,942 free-living adults, where PA and SLD were measured using a validated self-reported questionnaire and transient elastography, respectively. We further identified 1-year gut microbial changes and serum metabolites related to moderate-to-vigorous PA (MVPA), and examined their associations with SLD in a subset of the cohort (n=754), where fecal samples for 16S rRNA sequencing were collected twice (1-year apart), species-level microbial profiles were generated using shotgun metagenomics, targeted metabolomics was performed using baseline serum samples, and PA was assessed by accelerometer.</p><p><strong>Results: </strong>From 2020 to 2025, 565 SLD cases were newly diagnosed. MVPA levels were inversely associated with SLD risk (HR_T3vs.T1=0.78, 95% CI: 0.63-0.98), while sedentary hours were positively associated with SLD (HR_T3vs.T1=1.26, 95% CI: 1.00-1.58). Twelve genera showed longitudinal changes in relation to MVPA (p_FDR<0.05). Proteus was positively associated with SLD risk (OR=1.32, 95% CI: 1.01-1.72), supported by species-level shotgun metagenomics for Proteus cibarius. L-valine concentrations were inversely correlated with MVPA (β=-0.23, p_FDR=0.031), while demonstrating a positive association with SLD risk (OR=1.78, 95% CI: 1.22-2.63). L-valine was also correlated with the MVPA-associated genus Synergistes.</p><p><strong>Conclusions: </strong>MVPA is associated with changes in the gut microbiota and microbiota-related metabolites that are linked to a more favorable SLD profile, whereas sedentary behavior is associated with higher SLD risk.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102443"},"PeriodicalIF":6.2,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149007740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modification by cofactors in the impacts of body mass index change on the risk of biliary tract cancers.","authors":"Su Youn Nam, Junwoo Jo, Chang-Min Cho","doi":"10.1016/j.aohep.2026.102442","DOIUrl":"10.1016/j.aohep.2026.102442","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The impact of body mass index (BMI) change on the risk of biliary tract cancer, considering effect modification by age, smoking, and menopausal status, remains unexplored.</p><p><strong>Patients and methods: </strong>Cancer-free individuals who underwent health examinations in 2010 and 2014 were followed until 2021. BMI categories included underweight, normal, overweight, obesity I, and obesity II, with BMI changes classified into 25 groups using baseline and follow-up BMI. We assessed cancer risk according to BMI change and modification by cofactors using Fine and Gray's sub-distribution hazard model.</p><p><strong>Results: </strong>Among 3.8 million persons, 5047 gallbladder and 8339 bile duct cancers were detected. Persistent high BMI elevated the risk of BTC compared to persistent normal BMI. Among obese individuals, a modest BMI loss (from obesity I to overweight) decreased gallbladder cancer risk (aHR 0.87; 95% CI 0.77-0.99), wherein marked BMI loss (from obesity I to normal) increased bile duct cancer risk (aHR 1.30; 95% CI 1.07-1.58). Excessive BMI gain (from normal to obesity I) increased gallbladder cancer risk in smokers (aHR 1.71; 95% CI 1.01-2.92). The effect of BMI change on the risk of BTC was more pronounced in women, never smokers, and those under 60 years. Among overweight women, BMI loss and excessive BMI gain increased bile duct cancer risk in premenopausal women. The impact of persistent high BMI and BMI change on the risk of BTC was prominent in postmenopausal women.</p><p><strong>Conclusions: </strong>Maintaining a normal BMI is crucial for preventing BTCs. Excessive BMI changes confer varying risks by sex, age, smoking, and menopausal status.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102442"},"PeriodicalIF":6.2,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of liver function on clinical outcomes in patients with unresectable hepatocellular carcinoma treated with first-line atezolizumab-bevacizumab: An Asia-Pacific multicenter retrospective analysis.","authors":"Yeokyeong Shin, Young Jae Kim, David Wai Meng Tai, Hyung-Don Kim, Jonggi Choi, Won-Mook Choi, Sung Won Chung, Landon L Chan, Tsung-Hao Liu, Ilwhan Kim, Joycelyn Lee, Chiun Hsu, Stephen L Chan, Changhoon Yoo","doi":"10.1016/j.aohep.2026.102441","DOIUrl":"10.1016/j.aohep.2026.102441","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Atezolizumab+bevacizumab (atezo-bev) is the standard first-line therapy for unresectable hepatocellular carcinoma (uHCC), but pivotal trials were limited to patients with preserved liver function. Therefore, this study aims to evaluate the prognostic effect of Child-Pugh (CP) class and Albumin-Bilirubin (ALBI) grade in real-world patients receiving first-line atezo-bev.</p><p><strong>Materials and methods: </strong>This multinational, multicenter retrospective study included patients with uHCC receiving first-line atezo-bev at five institutions in the Republic of Korea, Singapore, Taiwan, and Hong Kong (July 2016-March 2025). Patients with CP-C were excluded.</p><p><strong>Results: </strong>Among 836 patients (median age, 64 years; 83.5% male), 90.4% had CP-A and 9.6% CP-B; ALBI grades 1, 2, and 3 comprised 41.8%, 55.7%, and 2.4%, respectively. Compared with CP-A, CP-B patients had lower ORR (15.0% vs. 25.4%, p = 0.040) and shorter median PFS (2.7 vs 6.3 months, p < 0.001) and OS (5.4 vs 18.6 months; p < 0.001). In contrast, ORR was similar across ALBI grades (23.8%, 25.1%, and 20.0% for grades 1-3, respectively; p = 0.816), both median PFS (7.0 vs. 5.6 vs. 2.6 months; p < 0.001) and OS (23.0 vs. 12.7 vs. 4.7 months; p < 0.001) worsened with higher ALBI grade. In multivariate analyses, CP class independently predicted PFS and OS, while ALBI predicted OS.</p><p><strong>Conclusions: </strong>Liver function is a key prognostic factor in patients with uHCC treated with atezo-bev. These findings highlight the need to assess liver function when selecting systemic therapy and support further studies, including patients with impaired liver function.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102441"},"PeriodicalIF":6.2,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extrahepatic endocrine manifestations of chronic HCV infection.","authors":"Katerina Stefanaki, Efthymios-Leonidas Kaltsounis, Rodanthi Syrigou, Nikolaos D Karakousis, Sotirios Tsiodras, Dimitrios S Karagiannakis","doi":"10.1016/j.aohep.2026.102440","DOIUrl":"10.1016/j.aohep.2026.102440","url":null,"abstract":"<p><p>Chronic Hepatitis C virus (HCV) infection is associated with numerous clinically significant extrahepatic manifestations. Endocrine disorders, including thyroid diseases, insulin resistance (IR), metabolic syndrome (MetS), and diabetes mellitus (DM), are common in patients with HCV. Chronic inflammation, immune dysregulation, and direct viral effects on extrahepatic tissues contribute to the pathogenesis of these diseases. Achieving sustained virological response (SVR) with new Direct-Acting Antivirals (DAAs) has not only reduced liver-related events and improved patient outcomes but also prevented or reversed various extrahepatic endocrine disorders. However, the extent and durability of endocrine improvements vary across patient subgroups, particularly among those with advanced liver disease. Evidence indicates that some endocrine diseases persist in patients with liver cirrhosis, even after successful viral eradication. Consequently, patients diagnosed with HCV-mediated endocrine disorders, particularly those with advanced liver disease at the time of DAA initiation, require ongoing surveillance by a multidisciplinary team even after achieving HCV eradication.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102440"},"PeriodicalIF":6.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of incident overt hepatic encephalopathy using individual and composite measures of minimal hepatic encephalopathy: the PrO-MHE study.","authors":"Akash Roy, Utkarsh Bhattad, Shardhya Chakraborty, Shruti Keyal, Awanish Tewari, Nikhil Sonthalia, Sourish Roy, Rajat Khandelwal, Anand Kulkarni, Uday Chand Ghoshal, Jasmohan Bajaj, Rajender Reddy, Mahesh Kumar Goenka","doi":"10.1016/j.aohep.2026.102428","DOIUrl":"10.1016/j.aohep.2026.102428","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Psychometric hepatic encephalopathy score (PHES) is the gold standard for minimal hepatic encephalopathy (MHE), predicts overt HE (OHE), but remains cumbersome for routine care. Point-of-care (POC) tests such as Stroop (EncephalApp) and Animal Naming Test (ANT) are simpler but assess narrower cognitive domains. We evaluated whether integrating POC domains into a composite score could improve the prediction of incident OHE.</p><p><strong>Patients and methods: </strong>153 outpatients underwent PHES, Stroop, and ANT. The primary endpoint was incident OHE within 180 days; death and liver transplantation were competing events. Cognitive predictors were analysed using Fine-Gray competing-risks regression with MELD and prior OHE as prespecified covariates. A composite cognitive risk score (CCRS) was derived from the principal component of standardized Stroop and ANT scores and rescaled from 0 to 10 RESULTS: MHE was present in 48.4% of cases. During follow-up, 29 (18.9%) developed incident OHE. In univariable models, PHES, Stroop time, and the CCRS were associated with incident OHE, whereas ANT was not. In multivariable models adjusted for MELD and prior OHE, PHES was the strongest predictor of incident OHE (sHR 0.77; 95% CI 0.66-0.90; p = 0.001).Stroop (per 10-second prolongation) independently predicted OHE (sHR 1.05; 95% CI 1.03-1.07; p < 0.001). CCRS independently predicted OHE (sHR 1.37; 95% CI 1.04-1.82; p = 0.028) and pragmatically stratified patients into risk-based strata.</p><p><strong>Conclusions: </strong>In a competing-risks framework, PHES best predicts incident OHE. Among POC tests, Stroop outperformed ANT. A novel CCRS predicts OHE, risk-stratifies, but does not approximate PHES performance.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102428"},"PeriodicalIF":6.2,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}